Loading…
Develops and sells radiopharmaceuticals for cancer imaging and treatment, including its approved prostate cancer scan Illuccix.
Develops and sells radiopharmaceuticals for cancer imaging and treatment, including its approved prostate cancer scan Illuccix.
Earns from selling its prostate-cancer imaging kit, Illuccix, mainly in the US through radiopharmacies that prepare and deliver doses to imaging centers, and from smaller sales in Australia and elsewhere. Its pipeline of imaging and treatment candidates is paid for from these sales and from capital raising.
In one line: Australia's Lantheus, a radiopharma innovator.
Moat: narrow (IP / patents, regulatory licence). FDA-approved radiopharmaceutical products and isotope supply chain are difficult and slow to replicate.
Headquarters: Melbourne, Australia · Founded: 2015 · Employees: 1,184
Size Telix Pharmaceuticals (TLX.AX) is an Australia Health Care company (Biotechnology) with a market value of $3.22B, the 94th largest of 316 Australia companies the cockpit tracks. Shares closed at A$13.67 on 6 Nov 2026.
Performance Over six months the shares fell 5.8%, against +3.9% for the median peer and +4.1% for the Australia market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 26.7% over the last twelve months (peer median +8.0%); the operating margin is -0.7% (peer median 4.2%).
Valuation It trades at 36.8× forward earnings against a peer median of 21.4× (3rd most expensive of 9).
Capital Return on invested capital runs 9.4 points below its cost of capital (8.9% WACC).
Next results Next results expected around 19 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | A$1.31B | A$1.25B | A$783M | A$503M | A$160M |
| Revenue growth | — | +59% | +56% | +214% | — |
| Gross profit | A$683M | A$662M | A$510M | A$315M | A$29.3M |
| EBITDA | A$45.2M | A$61.3M | A$90.2M | A$58.4M | -A$67.8M |
| Net income | A$47.2M | -A$11.0M | A$49.9M | A$5.21M | -A$104M |
| Free cash flow | -A$88.7M | -A$85.6M | A$14.2M | A$14.2M | -A$71.0M |
| Capital expenditure | A$68.2M | A$86.8M | A$48.5M | A$10.8M | A$13.9M |
| Total debt | n/a | A$700M | A$581M | A$17.4M | A$10.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Telix Pharmaceuticals TLX.AX | $3.22B | -6% | +27% | -1% | 36.8× | n/a |
| Lantheus LNTH | $6.57B | +8% | +2% | 19% | 17.5× | -0.5% |
| Novartis NOVN.SW | $298B | +15% | -4% | 30% | 18.4× | 1.7% |
| Clarity Pharmaceuticals CU6.AX | $386M | -48% | n/a | n/a | n/a | n/a |
| Perspective Therapeutics CATX | n/a | -78% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TLX.AX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.8% | +2.9% | 4th lowest of 21 |
| 6-month return | -5.8% | +3.9% | 9th lowest of 21 |
| Distance from 52-week high | -25.0% | -25.7% | 11th highest of 21 |
| Revenue growth (TTM) | +26.7% | +8.0% | 6th highest of 16 |
| Operating margin | -0.7% | 4.2% | 9th highest of 17 |
| Forward P/E | 36.8× | 21.4× | 3rd most expensive of 9 |
| ROIC minus cost of capital | -9.4 pp | -4.6 pp | 8th lowest of 17 |
| Net debt / EBITDA | 10.5× | 0.5× | 2nd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Telix Pharmaceuticals TLX.AX | Australia | $3.22B | -6% | +27% | -1% | 36.8× | n/a | n/a |
| Denali Therapeutics DNLI | United States | $3.22B | +2% | n/a | -2,488% | n/a | n/a | n/a |
| XtalPi 2228.HK | Hong Kong | $3.35B | -34% | +4% | -127% | n/a | n/a | n/a |
| Hualan Biological Engineering 002007.SZ | China | $3.37B | -15% | -11% | 17% | 25.5× | 16.7% | -1.8% |
| Dyne Therapeutics DYN | United States | $3.37B | +3% | n/a | n/a | n/a | n/a | n/a |
| Virbac VIRP.PA | France | $3.38B | +5% | +4% | 15% | 17.2× | 6.2% | +9.4% |
| HLB 028300.KS | South Korea | $3.06B | -49% | +29% | -96% | n/a | n/a | n/a |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.01B | -37% | -54% | -6,983% | n/a | n/a | n/a |
| Disc Medicine IRON | United States | $3.50B | +16% | n/a | n/a | n/a | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.93B | +27% | -3% | 16% | 17.1× | -2.0% | +27.4% |
| Zai Lab 9688.HK | Hong Kong | $2.92B | +13% | +5% | -59% | n/a | n/a | n/a |
| Rubicon Research RUBICON.NS | India | $2.91B | +74% | +37% | 21% | 77.2× | n/a | n/a |
| Enliven Therapeutics ELVN | United States | $3.62B | +21% | n/a | n/a | n/a | n/a | n/a |
| Tango Therapeutics TNGX | United States | $3.63B | -7% | +121% | -253% | n/a | n/a | n/a |
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.85B | -9% | +20% | -3% | n/a | n/a | n/a |
| Iovance Biotherapeutics IOVA | United States | $3.64B | +64% | +35% | -91% | n/a | n/a | n/a |
| ADMA Biologics ADMA | United States | $2.85B | +56% | +8% | 42% | 15.7× | -0.8% | +64.6% |
| Lin BioScience 6696.TWO | Taiwan | $3.74B | +129% | n/a | n/a | n/a | n/a | n/a |
| Xeris Biopharma XERS | United States | $2.77B | +133% | +36% | 11% | 67.9× | 33.3% | +70.2% |
| Beijing Tiantan Biological Products 600161.SS | China | $3.76B | -11% | -13% | 21% | 33.6× | 3.2% | +12.5% |
| Xiamen Amoytop Biotech 688278.SS | China | $2.76B | -23% | +18% | 27% | 16.2× | 0.5% | +36.0% |